Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023
23. Juni 2023 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, June 23, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing medicinal cannabinoid...
Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial
16. Juni 2023 08:00 ET
|
Incannex Healthcare
MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board
30. Mai 2023 08:00 ET
|
Incannex Healthcare
Highlights: Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board.Dr. Bill Richards is among the world’s best known psychedelic researchers and practitioners. He has...
Incannex Company Presentation – Presentation of Psychennex, Psychedelic Therapies Subsidiary Company
16. Mai 2023 07:50 ET
|
Incannex Healthcare
MELBOURNE, Australia, May 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation which details...
Incannex enters a lease for first psychedelic-assisted psychotherapy clinic
05. Mai 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, May 05, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a medicinal cannabinoid and psychedelic pharmaceutical...
Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A
03. Mai 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data...
Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A
02. Mai 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique...
Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU
14. April 2023 07:30 ET
|
Incannex Healthcare
MELBOURNE, Australia, April 14, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal...
Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts
16. März 2023 08:51 ET
|
Incannex Healthcare
Highlights: Incannex plans to open multiple psychedelic-assisted psychotherapy clinics in Australia and overseas.First clinic will open in Melbourne in 2023, followed by rapid expansion based...
Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment
15. März 2023 07:30 ET
|
Incannex Healthcare
Highlights: Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit...